An Open-label, Phase II Clinical Trial of Panitumumab in Combination With FOLFIRI Chemotherapy as Second Line Treatment in Subjects With Metastatic Colorectal Cancer Expressing Wild-type KRAS and Who Had Progressed greater than or equal to 6 Months After the Last Dose of the First Line Chemotherapy.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 15 Jan 2013
At a glance
- Drugs Panitumumab (Primary) ; Fluorouracil; Folinic acid; Irinotecan
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms ACTIVE
- 09 Nov 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 16 Jun 2010 New trial record